Literature DB >> 8508410

Increased risk of cancer in patients with Gaucher disease.

A Shiran1, B Brenner, A Laor, I Tatarsky.   

Abstract

BACKGROUND: An increased incidence of cancer, especially hematopoietic in origin, has long been suspected but never established in patients with Gaucher disease.
METHODS: To determine whether patients with Gaucher disease have an increased risk of cancer, the authors conducted a retrospective cohort study, comparing the incidence and type of cancer in 48 patients with Gaucher disease with those of 511 control subjects without the disease.
RESULTS: Among patients with Gaucher disease, 10 of 48 (20.8%) had cancer, as compared with 35 of 511 (6.8%) of the control group (P = 0.0027; relative risk, 3.6; 95% confidence interval, 1.7-7.5). As compared with the control group, patients with Gaucher disease had a 14.7-fold risk of having cancer of hematopoietic origin (10.4% [5 of 48] versus 0.78% [4 of 511], respectively; P = 0.00037; 95% confidence interval, 5.2-41.7). The mean age at cancer diagnosis in the group with Gaucher disease was 57 +/- 18 years.
CONCLUSIONS: The authors conclude that patients with Gaucher disease have a significantly increased risk of cancer, occurring in late adulthood. Of all the cancers, hematologic cancers are significantly more prevalent.

Entities:  

Mesh:

Year:  1993        PMID: 8508410     DOI: 10.1002/1097-0142(19930701)72:1<219::aid-cncr2820720139>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

2.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

3.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

4.  Extraosseous extension caused by epidural hematoma in Gaucher disease mimicking malignant bone tumor.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Ryo Shimizu; Mitsuo Ochi
Journal:  JIMD Rep       Date:  2013-12-21

5.  Extraosseous Gaucher cell deposition without adjacent bone involvement.

Authors:  Brendan J Meyer; Anne M Mills; Cree M Gaskin
Journal:  Skeletal Radiol       Date:  2014-06-22       Impact factor: 2.199

6.  Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Authors:  Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

7.  Gaucher disease: resetting the clinical and scientific agenda.

Authors:  Pramod K Mistry; Neal J Weinreb; Roscoe O Brady; Gregory A Grabowski
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

8.  Natural autoantibodies in sera of patients with Gaucher's disease.

Authors:  Y Shoenfeld; A Beresovski; D Zharhary; Y Tomer; M Swissa; E Sela; A Zimran; S Zevin; B Gilburd; M Blank
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

9.  Rare Case of Hepatic Gaucheroma in a Child on Enzyme Replacement Therapy.

Authors:  Sophy Korula; Penny Owens; Amanda Charlton; Kaustuv Bhattacharya
Journal:  JIMD Rep       Date:  2016-06-23

Review 10.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.